12.Lu, CH., Chung, WM., Tsai, CH. et al. In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction. Sci Rep 12, 303 (2022).
产品名:BMS202;PD1-PDL1 inhibitor 2;PD-1/PD-L1抑制剂;PD-1抑制剂;PD-L1抑制剂;small-molecule inhibitor;小分子抑制剂 CAS号:1675203-84-5 结构式:Cc1c(cccc1c2ccccc2)COc3ccc(c(n3)OC)CNCCNC(=O)C 分子式:C25H29N3O3 分子量:419.52 闪点:323.6±31.5 °C 沸点:611.4±55.0 °C at 760 mmHg...
11.Zak KM, Grudnik P, Guzik K, et al. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). Oncotarget. 2016;7(21):30323-30335. 12.Lu, CH., Chung, WM., Tsai, CH. et al. In vitro characterization of a small molecule PD-1 inhibitor that targets...
BMS-202基础信息 产品名：BMS202;PD1-PDL1 inhibitor 2;PD-1/PD-L1抑制剂;PD-1抑制剂;PD-L1抑制剂；small-molecule inhibitor；小分子抑制剂 CAS号：1675203-84-5 结构式：Cc1c(cccc1c2ccccc2)COc3ccc(c(n3)OC)CNCCNC(=O)C 分子式：C25H29N3O3 分子量：419.52 闪点：323.6±31.5 °C 沸点：61...
[13].Qian Wu, Li Jiang, Si-Cheng Li, et al. Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway. Acta Pharmacol Sin. 2021 Jan;42(1):1-9. [14].Julia A Beaver, Richard Pazdur. The Wild West of Chec...
12.Lu, CH., Chung, WM., Tsai, CH. et al. In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction. Sci Rep 12, 303 (2022). 声明:本文仅是介绍医药疾病领域研究进展或简述研究概况或分享医药相关讯息,并非也不会进行治疗或诊断方案推荐,也不对相关...
12.Lu, CH., Chung, WM., Tsai, CH. et al. In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction. Sci Rep 12, 303 (2022).
[13].Qian Wu, Li Jiang, Si-Cheng Li, et al. Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway. Acta Pharmacol Sin. 2021 Jan;42(1):1-9. [14].Julia A Beaver, Richard Pazdur. The Wild West of Checkpoint Inhibitor Development. N Engl J Med. 2021 Dec 15. ...
[3] Wu, Qian et al. “Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway.” Acta pharmacologica Sinica, 10.1038/s41401-020-0366-x [4] Fattakhova, Elena et al. “Identification of the FDA-Approved Drug Pyrvinium as a Small-Molecule Inhibitor of the PD-1/PD-L1 Interacti...
Checkpoints signalling reporter assays as well cell based PD-L1 dimerization assays were used to assess the mechanistic and functional effects.In vivoefficacy was assessed in orthotopic GBM as well as in syngeneic and humanized subcutaneous tumor models in mice.Results:Our lead PD-L1 inhibitor JBI-...